Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Evommune, Inc.NYSE: EVMN
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue remains negative
Q1 FY2026 deferred revenue was $0, compared with $0 a year earlier.
Context
- Deferred revenue amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Deferred revenue increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 3M | — |
| FY2023 | 2023-12-31 | 0 | — |
Deferred Revenue vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 deferred revenue of $0 is the 6th highest of the 10 companies compared; the peer median is $621K.
- Deferred revenue amounts to 0.0% of total assets for EVMN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $502.7M | +31.7% | +20.4% | 18.5% |
| Sep 2026 | $16.66M | +421.1% | +0.9% | 1.4% | |
| Mar 2026 | $2.94M | +70.4% | -27.2% | 1.0% | |
| Mar 2026 | $866K | +97.7% | -20.1% | 0.7% | |
| Jun 2026 | $621K | -15.2% | -14.0% | 0.0% | |
EVMNEvommune, Inc. | Mar 2026 | $0 | — | — | 0.0% |
CLYMClimb Bio, Inc. | Mar 2026 | $0 | — | — | 0.0% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EVMN) | $621K | +51.0% | -14.0% | 0.0% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.